Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
180 NOK | +2.86% | +2.27% | -15.89% |
Apr. 25 | Transcript : Medistim ASA, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 24 | Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.82 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.89% | 290M | - | ||
+8.38% | 219B | B | ||
+7.07% | 183B | B- | ||
+11.21% | 133B | B- | ||
+25.51% | 108B | A- | ||
+1.33% | 63.06B | A- | ||
+12.22% | 52.02B | B+ | ||
-0.62% | 48.2B | B+ | ||
+0.04% | 40.37B | A | ||
+13.11% | 39.35B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MEDI Stock
- Ratings Medistim ASA